Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Oslo Bors  >  PCI Biotech Holding ASA    PCIB   NO0010405640

PCI BIOTECH HOLDING ASA

(PCIB)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancials 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

PCI Biotech Holding ASA publishes the Annual Report 2019

share with twitter share with LinkedIn share with facebook
04/22/2020 | 02:00am EDT

Oslo, Norway, April 22, 2020. The Board of Directors of PCI Biotech Holding ASA has approved the Annual Report 2019 and the report is attached.
The Annual Report 2019 is also available on the company’s website www.pcibiotech.com.

For further information, please contact:             
PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo       
Per Walday, CEO, pw@pcibiotech.no, Mobile: +47 917 93 429  
Ronny Skuggedal, CFO, rs@pcibiotech.no, Mobile: +47 940 05 757

About PCI Biotech         
PCI Biotech is a biopharmaceutical late stage clinical development company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform. PCI is applied to three distinct anticancer paradigms: fimaChem (enhancement of chemotherapeutics for localised treatment of cancer), fimaVacc (T-cell induction technology for therapeutic vaccination), and fimaNAc (nucleic acid therapeutics delivery).

Photochemical internalisation induces triggered endosomal release that is used to unlock the true potential of a wide array of therapeutic modalities. The company’s lead programme fimaChem consists of a pivotal study in bile duct cancer, an orphan indication with a high unmet need and without approved products. fimaVacc applies a unique mode of action to enhance the essential cytotoxic effect of therapeutic cancer vaccines, which works in synergy with several other state-of-the-art vaccination technologies. fimaNAc utilises the endosomal release to provide intracellular delivery of nucleic acids, such as mRNA and RNAi therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising field.

For further information, please visit: www.pcibiotech.com                       
Contact information: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo                

Forward-looking statements    
This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements. PCI Biotech disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Attachment

Primary Logo


© GlobeNewswire 2020
share with twitter share with LinkedIn share with facebook
Latest news on PCI BIOTECH HOLDING ASA
01:32pPCI BIOTECH : Update on the preclinical research collaboration agreement with As..
GL
05/27PCI BIOTECH : Minutes from Annual General Meeting 2020
GL
05/06PCI BIOTECH : Notice of Annual General Meeting 2020
GL
05/06PCI BIOTECH : Q1 2020 Interim Report
PU
05/06PCI BIOTECH : First quarter 2020 results
GL
04/30PCI Biotech appoints Mr Ludovic Robin as Chief Business Officer
GL
04/28PCI BIOTECH : Invitation to Q1 2020 results presentation
PU
04/28PCI BIOTECH : Invitation to Q1 2020 results presentation
GL
04/22PCI Biotech Holding ASA publishes the Annual Report 2019
GL
03/31PCI Biotech appoints Dr Amir Snapir as Chief Medical Officer
GL
More news
Financials
Sales 2019 9,39 M 1,00 M 1,00 M
Net income 2019 -88,7 M -9,46 M -9,46 M
Net cash 2019 260 M 27,7 M 27,7 M
P/E ratio 2019 -32,2x
Yield 2019 -
Capitalization 2 620 M 280 M 279 M
EV / Sales 2018 65,5x
EV / Sales 2019 277x
Nbr of Employees 9
Free-Float 65,1%
Chart PCI BIOTECH HOLDING ASA
Duration : Period :
PCI Biotech Holding ASA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PCI BIOTECH HOLDING ASA
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Managers
NameTitle
Per Walday Chief Executive Officer
Hans Peter Bøhn Chairman
Ronny Skuggedal Chief Financial Officer
Anders Høgset Chief Scientific Officer
Amir Snapir Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
PCI BIOTECH HOLDING ASA-8.34%278
GILEAD SCIENCES, INC.17.45%95 734
VERTEX PHARMACEUTICALS34.48%76 344
REGENERON PHARMACEUTICALS65.35%63 051
WUXI APPTEC CO., LTD.59.57%33 311
GENMAB A/S56.13%22 955